Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Tauopathies 1Neurodegenerative Diseases 1Neurocognitive Disorders 1Nervous System Diseases 1Mental Disorders 1Inflammation 1Dementia 1Central Nervous System Diseases 1Brain Diseases 1Alzheimer Disease 1

Interventions

salicylsalicylic acid 1XENP 1595 1Pioglitazone 1Interleukin 1 Receptor Antagonist Protein 1Etanercept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Inflammation × XENP 1595 × Clear all
NCT05522387 2026-02-27

An Open-Label Extension of XPro1595 in Patients With Alzheimer's Disease

Inmune Bio, Inc.

Phase 2 Terminated
11 enrolled
CNS

Alzheimer Disease, Mental Disorders, Brain Diseases, Central Nervous System Diseases, Dementia, Inflammation, Nervous System Diseases, Neurodegenerative Diseases, Neurocognitive Disorders, Tauopathies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡